Pacific Biosciences of California, Inc. (PACB)
| Market Cap | 471.12M +9.1% |
| Revenue (ttm) | 160.01M +3.9% |
| Net Income | -546.38M |
| EPS | -1.82 |
| Shares Out | 302.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,370,526 |
| Open | 1.550 |
| Previous Close | 1.570 |
| Day's Range | 1.515 - 1.630 |
| 52-Week Range | 0.851 - 2.730 |
| Beta | 2.33 |
| Analysts | Hold |
| Price Target | 1.67 (+7.05%) |
| Earnings Date | May 7, 2026 |
About PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified... [Read more]
Financial Performance
In 2025, PACB's revenue was $160.01 million, an increase of 3.89% compared to the previous year's $154.01 million. Losses were -$546.38 million, 76.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PACB stock is "Hold." The 12-month stock price target is $1.67, which is an increase of 7.05% from the latest price.
News
PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing
Expands access to streamlined genomic data analysis across the PacBio partner ecosystem Expands access to streamlined genomic data analysis across the PacBio partner ecosystem
PacBio to Report First Quarter 2026 Financial Results on May 7, 2026
MENLO PARK, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2026 financial results on Thur...
PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples
New extraction-to-library prep workflow enables highly accurate long-read sequencing from archived clinical samples, expanding opportunities in cancer research New extraction-to-library prep workflow ...
Basecamp Research Selects PacBio HiFi Sequencing to Power Trillion Gene Atlas Initiative
PacBio's Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics PacBio's Revio system and SPRQ-Nx chemistry to...
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing Proven experience in leveraging AI in biolog...
Pacific Biosciences of California Transcript: TD Cowen 46th Annual Health Care Conference
The company is poised for significant growth in 2026, driven by the rollout of SPARQ-Nx chemistry, expanding clinical applications, and global market penetration. Improved economics, strong consumables growth, and a robust product portfolio position it to capture larger projects and increase profitability.
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
Collaboration powers secure international data sharing through the HiFi Solves Global Consortium Collaboration powers secure international data sharing through the HiFi Solves Global Consortium
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate...
Pacific Biosciences of California Earnings Call Transcript: Q4 2025
Q4 and full year 2025 saw record consumable revenue and strong instrument placements, with clinical adoption driving growth despite academic funding headwinds. 2026 guidance projects 8% revenue growth, margin expansion, and continued focus on long-read sequencing and cost discipline.
PacBio Completes Sale of Short-Read Sequencing Assets
MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of se...
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial r...
Pacific Biosciences of California Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong Q4 and 2025 growth were driven by clinical market expansion, record consumables sales, and new product launches. SPRQ Next Chemistry is lowering sequencing costs and boosting demand, with Europe leading growth and clinical adoption accelerating globally.
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic models The planned collaboration highlights the role of complete genome resolution in scaling ...
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio's Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving families Trios from 200 families...
PacBio and UC Davis Researchers Introduce CiFi, a New Long-Read 3C Method That Enables Chromosome-Scale Assemblies from a Single SMRT Cell
Community-developed approach combines multi-contact 3C with HiFi sequencing to deliver haplotype-resolved assemblies from minimal input material Community-developed approach combines multi-contact 3C ...
PacBio to Present at the 44th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenti...
PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate...
Pacific Biosciences of California Transcript: Stephens Annual Investment Conference
Long read sequencing is approaching cost parity with short read, driving increased adoption in clinical and population genomics. New chemistries and instruments are expanding the customer base, while operational discipline and product innovation support the goal of cash flow positivity by 2027.
Pacific Biosciences of California Transcript: Wolfe Research Healthcare Conference 2025
Long-read sequencing focus and operational discipline are driving margin improvements and product innovation. New launches and early access programs are expanding both usage and customer base, with international projects and clinical adoption set to boost 2026 growth.
Pacific Biosciences of California Earnings Call Transcript: Q3 2025
Q3 2025 revenue was $38.4M, with record consumables and 42% non-GAAP gross margin. EMEA led growth, while funding challenges persisted in the Americas and Asia-Pacific. SPRQ-Nx chemistry and clinical initiatives are expected to drive future growth and margin improvement.
HiFi Solves Consortium Publishes First Major Study Demonstrating the Clinical Research Power of PacBio HiFi Genomes
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research...
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia NMPA approval on the Sequel I...
PacBio to Report Third Quarter 2025 Financial Results on November 5, 2025
MENLO PARK, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2025 financial results on Wedne...
PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than ...
PacBio HiFi Technology Selected as Core Platform for South Korea's National Pangenome Project
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine More than 1,000 Korean genomes to be sequenced for global reference sta...